Authorizing Cannabis for Medical Purposes

Policy document

LAST REVIEWED 2020-02-29

DATE 2015-02-28

TOPICS Pharmaceuticals, prescribing, cannabis, drugs

The Canadian Medical Association (CMA) recognizes the medical use of cannabis in the form of a pharmaceutical product for patients who have been diagnosed with medical conditions that may benefit from its use. The CMA advocates for the legalization of cannabis for medical purposes, provided it is regulated and controlled to ensure the safety and health of patients.

CMA POLICY

Authorizing Cannabis for Medical Purposes

The legalization of cannabis for medical purposes is a complex issue, and the CMA supports evidence-based policies that ensure the safe and effective use of cannabis for medical purposes. The CMA recommends that cannabis products be regulated by a federal ministry, ensuring that they are manufactured under conditions that meet high standards of safety and quality.

The CMA supports the establishment of a regulatory framework that allows for the legal production, distribution, and dispensing of cannabis products for medical use. This framework should ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a regulatory body responsible for the production, distribution, and dispensing of cannabis products for medical use. This body should be independent of the federal ministry responsible for cannabis legalization and should have the authority to monitor and regulate the supply chain of cannabis products.

The CMA supports the provision of educational resources to healthcare providers to ensure they have the knowledge and skills necessary to address the medical needs of patients who use cannabis for medical purposes. This includes training in the safe and effective use of cannabis products, as well as communication with patients about the potential risks and benefits of cannabis use.

The CMA advocates for the development of research into the therapeutic effects of cannabis and its active compounds. This research should be conducted in a manner that is consistent with ethical standards and should be funded by the federal government.

The CMA supports the establishment of a national database to track the use of cannabis products for medical purposes. This database should be accessible to healthcare providers and should be used to monitor trends in cannabis use and to inform policy decisions.

The CMA encourages healthcare providers to consider the potential benefits and risks of cannabis use in the context of individual patient needs. Providers should be aware of the potential for cannabis to interact with other medications and should monitor patients for any adverse effects.

The CMA supports the development of guidelines for the use of cannabis products for medical purposes. These guidelines should be evidence-based and should be developed in collaboration with healthcare providers and patients.

The CMA advocates for the provision of support services for patients who use cannabis for medical purposes. This includes access to counseling, support groups, and other resources that can help patients manage the use of cannabis in a safe and effective manner.

The CMA supports the establishment of a patient advocacy group to represent the interests of patients who use cannabis for medical purposes. This group should be comprised of patients, healthcare providers, and other stakeholders.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.

The CMA recommends that the federal government establish a system for the compensation of patients who suffer harm due to the use of cannabis products for medical purposes. This system should be based on the principles of fairness and accountability.

The CMA supports the establishment of a monitoring system to track the use of cannabis products for medical purposes. This system should be designed to ensure that patients have access to safe and effective cannabis products, while also protecting public health and safety.
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11519

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2015-05-14</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents

![Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)](image)

Policybase - Canadian Medical Association
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE Parliamentary submission
DATE 2014-06-11
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE  Parliamentary submission
DATE  2017-08-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of CMA Submission: Bill C-45: The Cannabis Act]

Submission to the House of Commons Standing Committee on Health

August 18, 2017
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE: Parliamentary submission
DATE: 2018-04-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada's lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE: Policy endorsement
DATE: 2017-05-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

POLICY TYPE          Parliamentary submission
DATE                2014-05-15
TOPICS              Health care and patient safety
                                   Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology – Prescription Drugs: Clinical Trials and Approval
https://policybase.cma.ca/link/policy10437

POLICY TYPE  Parliamentary submission
DATE  2012-05-09
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal

https://policybase.cma.ca/link/policy10702

POLICY TYPE
Parliamentary submission

DATE
2013-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations

https://policybase.cma.ca/link/policy13690

POLICY TYPE  
Response to consultation

DATE  
2017-06-28

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-02-15</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs Health care and patient safety</td>
</tr>
</tbody>
</table>

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE  2015-06-08
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the House of Commons Standing Committee on Health:
Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE
Parliamentary submission

DATE
2012-03-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE Parliamentary submission
DATE 2014-03-26
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE
Parliamentary submission

DATE
2012-10-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Complementary and alternative medicine (update 2015)

https://policybase.cma.ca/link/policy11529

POLICY TYPE
Policy document

DATE
2015-05-30

REPLACES
Complementary and alternative medicine (Update 2008)

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents